Arena pharmaceuticals, inc. (ARNA)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Revenues:
Net product sales

-

-

-

-

-

15,983

5,702

-

0

-

-

Other collaboration revenue

-

-

-

-

-

-

-

-

-

9,556

3,808

Toll manufacturing

-

-

-

-

-

1,497

2,690

3,817

-

-

-

Manufacturing services

-

-

-

-

-

-

-

-

5,338

7,057

6,579

Total revenues

806,431

17,970

21,337

92,163

13,398

36,970

81,394

27,587

12,719

16,613

10,387

Operating Costs and Expenses:
Cost of product sales

-

-

-

-

-

6,369

1,803

0

0

-

-

Cost of toll manufacturing

-

-

-

-

-

1,390

4,377

3,671

-

-

-

Cost of manufacturing services

-

-

-

-

-

-

-

-

8,100

7,414

6,536

Research and development

231,496

115,029

70,988

63,782

83,283

100,347

66,468

54,112

58,706

75,459

110,159

General and administrative

77,616

45,257

30,341

27,529

30,281

34,137

31,681

26,226

24,248

27,936

25,247

Transaction costs

14,573

2,467

-

-

-

-

-

-

-

-

-

Litigation settlement expense, net

-

-

11,975

-

-

-

-

-

-

-

-

Restructuring charges

-

-

-

6,115

3,346

-

-

-

3,467

0

3,324

Restructuring charges

-

-

-

-

-

-

0

691

997

-

-

Amortization of acquired technology and other intangibles

-

-

-

-

-

-

-

-

-

2,159

3,508

Total operating costs and expenses

323,685

162,753

113,304

97,426

116,910

142,243

104,329

84,700

95,518

112,968

148,774

Income (loss) from operations

482,746

-144,783

-91,967

-5,263

-103,512

-105,273

-22,935

-57,113

-82,799

-96,355

-138,387

Interest and Other Income (Expense):
Interest income

26,872

8,772

492

290

158

83

89

119

117

469

689

Interest expense

4,791

5,695

6,119

6,512

6,828

6,915

7,091

9,120

14,309

21,681

18,718

Gain from valuation of derivative liabilities

-

-

-

-

474

4,418

10,150

-13,425

47

4,371

5,418

Gain on sale of available-for-sale securities

-

-

-

-

-

49,553

0

0

-

-

-

Loss on extinguishment of debt

-

-

-

-

-

-

-

-6,338

-10,514

-12,354

-2,479

Other income

3,061

2,872

1,740

-815

-999

-2,374

352

400

-1,766

1,016

273

Total interest and other income (expense), net

25,142

5,949

-3,887

-7,037

-7,195

44,765

3,500

-28,364

-26,425

-28,179

-14,817

Income (loss) before income taxes

507,888

-138,834

-95,854

-12,300

-

-

-

-

-

-

-

Income tax provision

110,333

-110,265

0

0

-

-

-

-

-

-

-

Income (loss) from continuing operations

397,555

-28,569

-95,854

-12,300

-110,707

-

-

-

-

-

-

Income (loss) from discontinued operations

-

-830

3,122

-10,596

2,728

-

-

-

-

-

-

Net income (loss)

397,555

-29,399

-92,732

-22,896

-107,979

-60,508

-

-

-

-

-

Less net loss attributable to noncontrolling interest in consolidated variable interest entity

-

-

-1,325

-380

-

-

-

-

-

-

-

Net income (loss)

397,555

-29,399

-91,407

-22,516

-107,979

-60,508

-19,435

-85,477

-109,224

-124,534

-153,204

Net income (loss) attributable to stockholders of Arena per share, basic:
Continuing operations

7.99

-0.61

-2.87

-

-

-

-

-

-

-

-

Discontinued operations

-

-0.02

0.10

-

-

-

-

-

-

-

-

Deemed dividend related to beneficial conversion feature of convertible preferred stock

-

-

-

-

-

-

-

2,824

2,260

0

0

Net loss allocable to common stockholders

-

-

-

-

-

-

-

-88,301

-111,484

-124,534

-153,204

Net income (loss) attributable to stockholders of Arena per share, basic and diluted:
Continuing operations

-

-

-

-0.49

-4.60

-

-

-

-

-

-

Discontinued operations

-

-

-

-0.44

0.11

-

-

-

-

-

-

Net income (loss) attributable to stockholders of Arena per share, basic and diluted

-

-

-

-0.93

-4.49

-

-

-

-

-

-

Shares used in calculating net income (loss) attributable to stockholders of Arena per share, basic and diluted

-

-

-

24,313

24,067

-

-

-

-

-

-

Net income (loss) per share, basic:

7.99

-0.63

-2.77

-

-

-0.28

-0.09

-0.45

-0.80

-1.14

-1.82

Net income (loss) attributable to stockholders of Arena per share, diluted:
Continuing operations

7.69

-0.61

-2.87

-

-

-

-

-

-

-

-

Discontinued operations

-

-0.02

0.10

-

-

-

-

-

-

-

-

Net income (loss) per share, diluted:

7.69

-0.63

-2.77

-

-

-0.28

-0.09

-0.45

-0.80

-1.14

-1.82

Shares used in calculating net income (loss) per share, basic:

49,779

47,041

32,990

-

-

219,734

218,104

196,523

139,170,725

109,573

84,341

Shares used in calculating net income (loss) per share, diluted:

51,698

47,041

32,990

-

-

219,734

218,104

196,523

139,170,725

109,573

84,341

Comprehensive Income (Loss):
Amounts attributable to stockholders of Arena:
Income (loss) from continuing operations

-397,555

28,569

94,529

11,920

-110,707

-

-

-

-

-

-

Income (loss) from discontinued operations

-

-830

3,122

-10,596

2,728

-

-

-

-

-

-

Net income (loss)

397,555

-29,399

-91,407

-22,516

-107,979

-

-19,435

-85,477

-109,224

-124,534

-153,204

Net income (loss)

397,555

-29,399

-92,732

-22,896

-107,979

-60,508

-

-

-

-

-

Foreign currency translation loss

-11

72

2,016

-1,920

-4,087

-2,820

239

746

-223

4,304

-

Unrealized gain (loss) on available-for-sale investments

1,469

-113

-133

-

-

-

-

-

-

-

-

Comprehensive income (loss)

399,013

-29,440

-90,849

-24,816

-112,066

-63,328

-

-

-

-

-

Less comprehensive loss attributable to noncontrolling interest in consolidated variable interest entity

-

-

-1,325

-380

-

-

-

-

-

-

-

Net unrealized loss on available-for-sale investments

-

-

-

-

-

-

-

-

-

-283

-

Comprehensive income (loss)

399,013

-29,440

-89,524

-24,436

-112,066

-63,328

-19,196

-84,731

-109,447

-120,513

-

Royalty Revenue
Total revenues

-853

6,568

1,705

-

-

-

-

-

-

-

-

Collaboration and Other Revenue
Total revenues

7,284

11,402

19,632

92,163

13,398

-

-

-

-

-

-

United Therapeutics
Transaction costs

14,600

2,400

-

-

-

-

-

-

-

-

-